Clinical Trials Directory

Trials / Completed

CompletedNCT01942759

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC

Status
Completed
Phase
Study type
Observational
Enrollment
43 (actual)
Sponsor
Bagcilar Training and Research Hospital · Other Government
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.

Detailed description

We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic value of these indexes in breast cancer in this study. The evaluated and compared parameters are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status, histologic grade, modified Nottingham prognostic index.

Conditions

Timeline

Start date
2013-09-01
Primary completion
2014-06-01
Completion
2014-06-01
First posted
2013-09-16
Last updated
2014-06-10

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT01942759. Inclusion in this directory is not an endorsement.

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer (NCT01942759) · Clinical Trials Directory